GLPwatch
Papers (12034)
Page 145 of 201, ranked by citation count.
- Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
- Exenatide in type 2 diabetes.
- Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.
- Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells.
- iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
- Accuracy of dosage volume for halfway doses in the Victoza Pen.
- In type 2 diabetes with increased CV risk, tirzepatide reduced HbA<sub>1c</sub> vs. glargine at 52 wk.
- Consumer group calls for antidiabetes drug to be withdrawn.
- Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson's disease when considering the coexisting effects of diabetes mellitus.
- More on Semaglutide in Early Type 1 Diabetes.
- Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis.
- The Effect of Lifestyle Coaching Design on Patient Engagement and Weight Loss in Non-diabetic Patients of a Semaglutide-Supported Digital Obesity Program in the UK: A Comparative Retrospective Cohort Study.
- Integrating micro-needle jet injection and sustained GLP-1 therapy with structured feeding: a comprehensive strategy for obesity management.
- Effect of Exenatide Therapy on Platelet Function in Type 2 Diabetes Mellitus.
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
- Diagnosis and management of hyperglycaemia in patients treated with antipsychotic drugs.
- Long-Term Effect of Semaglutide on the Glomerular Filtration Rate Slope in High-Risk Patients with Diabetic Nephropathy: Analysis in Real-World Clinical Practice.
- Integrating semaglutide into obesity management - a primary care perspective.
- Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
- Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
- Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes.
- Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.
- Exenatide Induces Impairment of Autophagy Flux to Damage Rat Pancreas.
- The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents.
- A microporous liraglutide-releasing silk fibroin scaffold improves islet transplantation outcomes through anti-inflammatory effect.
- Liraglutide preserves endothelial function in ophthalmic arteries of septic mice via prevention of oxidative stress.
- Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
- Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.
- In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
- Semaglutide may provide sustained weight loss for at least four years, study reports.
- [Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia/reoxygenation].
- GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.
- Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.
- Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation.
- Design of experiments approach for the development of a validated method to determine the exenatide content in poly(lactide-co-glycolide) microspheres.
- [Effect of adipose-derived mesenchymal stem cells and liraglutide on acute lung injury].
- Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expression: evidence from a randomized clinical trial.
- Exendin-4 induced retching-like behavior mediated by postsynaptic effect via AMPA receptors in the area postrema of mice.
- Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report.
- Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.
- Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.
- Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.
- [Severe gastroparesia associated with the use of GLP-1 receptor agonists for weight loss].
- Pharmacological Signatures of the Exenatide Nanoparticles Against Hepatic Ischemia/Reperfusion-induced Pancreatic Injury.
- Exendin-4 prevented pancreatic beta cells from apoptosis in (Type I) diabetic mouse via keap1-Nrf2 signaling.
- In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.
- Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.
- A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.
- Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.
- Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
- Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
- Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss.
- Clinical studies on anti-obesity medications in Arab countries.
- Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy.
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
- Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study.
- Tirzepatide-Induced Liver Injury: A Rare Complication.
- ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide.
- Non-invasive tests for fibrotic MASH: Decision aids in MASH therapeutics and predictors of liver-related events.
- GLP-1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?